Santen and Sydnexis have finalized an exclusive licensing agreement for SYD-101 in Europe, Middle East and Africa for the treatment of progressive childhood myopia, according to a press release.
SYD-101 (atropine sulfate ophthalmic solution 0.01% and 0.03%, Sydnexis) is an investigational formulation that is being evaluated in the phase 3 STAAR study in the United States and Europe, the release said.
“We are excited to partner with Santen, a global leader in ophthalmology, to help fulfill our goal of making SYD-101 available in EMEA. We recognize the expertise that Santen (Read more...)